White Paper: Pacific Biomarkers
Preanalytical considerations in the design of clinical trials and epidemiologic studies are the cornerstones of the biochemical analyses. The main subject of clinical study design and epidemiology research is to monitor health, detect the harmful side effects and study the impact of therapeutic interventions.
However, the largest contribution of errors in the clinical study design and epidemiology is associated with preanalytical phase.
Do you think preanalytical variables are given sufficient consideration when designing clinical trials or epidemiologic studies?
What strategies can be used to minimize preanalytical variables in clinical trials or epidemiologic studies?
Is there a technology or a process to improve stability of sample analytes so that future investigations will not suffer from poor sample quality?
What are the common challenges encountered during the preanalytical phase?
This whitepaper discusses the factors to be considered during clinical trial designing and challenges faced during preanalytical phase such as:
Availability of limited resources during the clinical designing.
Technology and storage processes used to store the biomarker samples.
Time elapsed between the sample collection and the stabilizing agents used to store the samples.
Download this whitepaper with a brief insight into the issues of preanalytical variables and how they impact the clinical trial design and epidemiologic studies.
By: Pacific Biomarkers
Testing for incretins, and other gut hormones, presents numerous challenges because of their instability. Therefore, proper sample collection and meticulous pre-analytical and analytical sample handling are crucial for successful quantification of these biomarkers. Incretins, which are insulinotropic gastrointestinal hormones, are produced mainly in K and L cells of the small intestine under the influence of nutritional stimuli. This insightful whitepaper sees into queries like: What are the significant challenges in the measurement of incretins and gut hormones? What is the best practice for minimizing pre-analytical variability associated with blood collection, processing and storage? What are the additional pre-analytical steps that should be considered when samples are obtained for quantification of active acylated ghrelin? Download this whitepaper that provides insights about the challenges, best practices and major concerns regarding commercial assays for reliable quantification of incretins and gut hormones and specific pre-analytical and analytical processes as well as data analysis to improve sensitivity.
By: Pacific Biomarkers
Biomarkers for the prediction of acute kidney injury: A review on current status and future challenges Biomarker of acute kidney injury (AKI) is strongly associated with increased morbidity and mortality in critically ill patients. The approach to analyzing AKI biomarkers has been to provide pharmaceutical and biotech companies with services for testing robust novel biomarkers that have undergone thorough analytical validation and clinical qualification with the expectation to diagnose early organ injury. Read this insightful whitepaper on ''Biomarkers for early detection of acute kidney injury'' to know more on: How to target biomarkers that can detect acute kidney injury (AKI) and what the potential of an AKI biomarker program is. What are the issues surrounding the best methods of collecting and storing urine used for detection of AKI in human subjects? Acute kidney injury biomarkers performance assesment